- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), a panel of urologists and radiation oncologists debate optimal treatment for high-risk prostate cancer, comparing surgery versus radiation and multimodal approaches. Patient advocate David Matheson emphasizes empowering patients with comprehensive information for informed decision-making. Biographies: Francesco Sanguedolce, MD, PhD...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Derya Tilki analyzes PSA persistence after radical prostatectomy, examining its prevalence, correlation with adverse outcomes, and role of PSMA PET/CT and genomic testing. She discusses current treatments and ongoing trials exploring intensification strategies for high-risk patients. Biographies: Derya Tilki, MD, Associate Professo...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Barbara Alicja Jereczek-Fossa examines timing decisions for post-prostatectomy salvage radiation, addressing PSA definitions and risk stratification tools. She emphasizes the importance of early intervention while discussing personalized treatment approaches and ongoing trials. Biographies: Barbara Alicja Jereczek-Fossa, MD, PhD, D...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Bertrand Tombal challenges traditional salvage radiation approaches in high-risk EMBARK patients. Based on trial results showing enzalutamide's survival benefits, he advocates shifting from radiation-first to systemic ARTA treatment, with radiation as a secondary consideration. Biographies: Bertrand Tombal, MD, PhD, Chairman of the...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Daniel Spratt examines systemic therapy in post-operative biochemical recurrence, challenging universal hormone therapy with salvage radiation. He demonstrates varying benefits based on PSA levels and emphasizes treatment personalization using genomic classifiers and MMAI models. Biographies: Daniel Spratt, MD, Chair and Professor...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Derya Tilki leads a panel with Drs Tombal, Spratt, and Alicja Jereczek-Fossa examining salvage radiation timing, EMBARK trial interpretation, and treatment decision factors in biochemically recurrent prostate cancer, balancing PSA levels and patient-specific characteristics. Biographies: Derya Tilki, MD, Associate Professor of Urol...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Paul Nguyen analyzes treatment approaches for post-prostatectomy and salvage radiation biochemical recurrence, comparing SBRT versus whole pelvis radiation for lymph node metastases. He examines current evidence and ongoing trials informing treatment decisions. Biographies: Paul L. Nguyen, MD, MBA, FASTRO, Baldwin-Politi Distinguis...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Neal Shore presents data from three clinical trials for enzalutamide monotherapy, highlighting that tamoxifen with early radiation therapy proves most effective for gynecomastia prophylaxis. The findings suggest these approaches may be applicable across other ARPIs. Biographies: Neal Shore, MD, FACS, Director, CPI (Certified Princi...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Ray McDermott presents a comprehensive discussion on managing biochemical relapse after surgery and salvage radiation in prostate cancer. The presentation explores treatment strategies based on PSA doubling time, highlighting the EMBARK study's findings and discusses the role of PSMA PET scans and metastasis-directed therapy. Biogr...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), a panel discussion explores several key topics in prostate cancer treatment, focusing on gynecomastia management and treatment approaches for recurrent disease. The experts debate the merits of prophylactic radiation versus tamoxifen for gynecomastia prevention, with most favoring upfront radiation due to its efficacy and fewer sid...
|
